Zenas Biopharma, Common Etf Analysis
| ZBIO Etf | USD 12.00 1.56 14.94% |
Zenas BioPharma, Common is overvalued with Real Value of 11.76 and Hype Value of 11.94. The main objective of Zenas BioPharma, etf analysis is to determine its intrinsic value, which is an estimate of what Zenas BioPharma, Common is worth, separate from its market price. There are two main types of Zenas Etf analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic stability of Zenas BioPharma, Common. On the other hand, technical analysis, focuses on the price and volume data of Zenas Etf to identify patterns and trends that may indicate its future price movements.
The Zenas BioPharma, etf is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Zenas |
Zenas Etf Analysis Notes
The fund keeps most of the net assets in exotic instruments. Zenas BioPharma, Common last dividend was 0.002 per share. The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States. For more information please call MBA Moulder at 857 271 2954 or visit https://zenasbio.com.Zenas BioPharma, Common Investment Alerts
| Zenas BioPharma, generated a negative expected return over the last 90 days | |
| Zenas BioPharma, has high historical volatility and very poor performance | |
| Zenas BioPharma, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (37.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| The fund created three year return of -33.0% | |
| Latest headline from benzinga.com: Top 3 Health Care Stocks Youll Regret Missing In Q4 | |
| Zenas BioPharma, Common keeps most of the net assets in exotic instruments. |
Zenas Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 673.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zenas BioPharma,'s market, we take the total number of its shares issued and multiply it by Zenas BioPharma,'s current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 25th of November, Zenas BioPharma, maintains the Market Risk Adjusted Performance of (11.53), mean deviation of 4.4, and Standard Deviation of 6.17. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zenas BioPharma, Common, as well as the relationship between them.Zenas BioPharma, Common Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fourty-one. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Zenas BioPharma, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Zenas BioPharma, Common. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Zenas BioPharma, Common Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zenas BioPharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zenas BioPharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zenas BioPharma, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Moulder Leon O Jr few days ago Acquisition by Moulder Leon O Jr of 2500 shares of Zenas BioPharma, at 14.57 subject to Rule 16b-3 | ||
Moulder Leon O Jr six days ago Acquisition by Moulder Leon O Jr of 7500 shares of Zenas BioPharma, at 15.0 subject to Rule 16b-3 |
Zenas BioPharma, Predictive Daily Indicators
Zenas BioPharma, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Zenas BioPharma, etf daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Zenas BioPharma, Forecast Models
Zenas BioPharma,'s time-series forecasting models are one of many Zenas BioPharma,'s etf analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zenas BioPharma,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Zenas Etf Analysis
Etf analysis is the technique used by a trader or investor to examine and evaluate how Zenas BioPharma, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Zenas shares will generate the highest return on investment. We also built our etf analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Etf such as Zenas BioPharma,. By using and applying Zenas Etf analysis, traders can create a robust methodology for identifying Zenas entry and exit points for their positions.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our etf analysis tools, you can find out how much better you can do when adding Zenas BioPharma, to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.